Explore more
News
Eli Lilly, Novo Nordisk and Zepbound
Digest more
Eli Lilly (NYSE: LLY) was an unstoppable bet in the past few years, but LLY stock finally started plateauing in the latter ...
A consultancy’s new ranking of drug company R&D shows Eli Lilly has risen to the top of the drug development heap, while ...
On Monday’s episode of Mad Money, Jim Cramer broke down the day’s market rally and argued in favor of staying invested, even ...
Now, this won't come as too much of a surprise to Eli Lilly and its peers. A few weeks ago, the company's CEO, David Ricks, ...
Stephanie Link, CIO at Hightower, joins CNBC's "Halftime Report" to detail her latest portfolio moves. Qatar pushes back on ...
The ALS therapy ATLX-1282 was developed with AIchemab's platform, which uses AI to identify therapeutic targets for difficult ...
The Lilly announcement will extend an agreement aimed at accelerating medicine development and bolstering the ...
Ricks said reshoring manufacturing capacity for older essential medicines is “a valid thing,” adding that Eli Lilly is “happy ...
5don MSN
The investment over the next eight years could be the largest ever industry-academic agreement of its kind in the U.S., the ...
1don MSN
There are significant questions on how the order can be implemented, and if companies can raise prices on already approved ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback